Sign Up for our Newsletter
Noninvasive prenatal testing for greater accuracy
More women deserve the right to NIPT
Noninvasive prenatal testing (NIPT) consists in analyzing cell-free DNA (cfDNA) circulating in the maternal blood in order to detect fetal chromosomal abnormalities. Testing can be performed as early as 10 weeks of pregnancy.
Safe and accurate
From a simple blood test, NIPT enables safe and early access to reliable results and helps reduce the number of unnecessary invasive procedures.
International scientific societies have recognized cell-free DNA testing as the most sensitive and specific screening test for the common fetal aneuploidies, and recommended that it is offered to all pregnant women.1,2
Expert Insights & Resources
Expand your knowledge with articles, training resources, news & webcasts for professionals and advocates alike.
Universal access to NIPT: Cost-effective and precise cell-free DNA testing
Making NIPT accessible to all women
Implementation and Validation of a High-Precision, Non-NGS NIPT Platform
Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies
What You Can Screen For
Trisomy 21 (Down syndrome)
Trisomy 18 (Edwards syndrome)
Trisomy 13 (Patau syndrome)
Vanadis® NIPT platform: Built for All
Unlike complex and expensive sequencing-based platforms, Vanadis NIPT enables cost-efficient and high-performance screening for fetal aneuploidies. Making cell-free DNA testing accessible to more laboratories and more women, Vanadis is built for all.
Take the next step
- Practice Bulletin Number 226: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2020; 136(4)
- Benn P, Borrell A, Chiu R, et al. Position statement from the Chromosome Abnormality Screening Committee. Prenat Diagn. 2015;35(8):725-734.
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.